Telangiectases in Scleroderma: A Potential Clinical Marker of Pulmonary Arterial Hypertension

Journal of Rheumatology - Canada
doi 10.3899/jrheum.090697
Full Text
Abstract

Available in full text

Date
Authors
Publisher

The Journal of Rheumatology

Related search

Pulmonary Arterial Hypertension Associated With Scleroderma

Advances in Pulmonary Hypertension
2008English

Borderline Pulmonary Pressures in Scleroderma - A ‘Pre-Pulmonary Arterial Hypertension’ Condition?

Arthritis Research and Therapy
RheumatologyAllergyImmunology
2015English

Scleroderma Associated Pulmonary Hypertension

Advances in Pulmonary Hypertension
2008English

Iron Deficiency in Pulmonary Arterial Hypertension: A Potential Therapeutic Target

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2011English

Ambrisentan and Tadalafil Up-Front Combination Therapy in Scleroderma-Associated Pulmonary Arterial Hypertension

American Journal of Respiratory and Critical Care Medicine
PulmonaryCritical CareRespiratory MedicineIntensive Care Medicine
2015English

Tadalafil: The Evidence for Its Clinical Potential in the Treatment of Pulmonary Arterial Hypertension

Core Evidence
MedicineReviewsReferencesPharmacology
2007English

Pulmonary Arterial Hypertension

Current Problems in Cardiology
MedicineCardiovascular MedicineCardiology
2011English

CCL21 as a Potential Biomarker for Pulmonary Arterial Hypertension in Systemic Sclerosis

Arthritis and Rheumatology
RheumatologyAllergyImmunology
2018English

Interleukin-6 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension

International Journal of Rheumatology
RheumatologyImmunology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy